Table 3

Disease-modifying antirheumatic drug (DMARD)/steroid treatment received over 10 years of follow-up

DMARD/steroid treatment between previous and current follow-up, n (%)
Year of follow-upCohort (n)Treated between previous and current follow-up, n (%)Sulfasalazine (SSZ)Methotrexate (MTX)Steroid (Ss)Other
0*1084226 (21)135 (60)15 (7)72 (32)17 (8)
11025450 (44)283 (63)69 (15)139 (31)36 (8)
2961418 (43)225 (54)91 (22)128 (31)40 (10)
3924396 (43)194 (49)114 (29)124 (31)38 (10)
5855374 (44)164 (44)144 (39)127 (34)32 (9)
7732305 (42)113 (37)150 (49)98 (32)25 (8)
10664293 (44)108 (37)159 (54)95 (32)22 (8)
Ever DMARD/steroid treatment by follow-up, n (%)
Year of follow-upCohort (n)Ever treated by follow-up, n (%)Sulfasalazine (SSZ)Methotrexate (MTX)Steroid (Ss)Other
01084226 (21)135 (60)15 (7)72 (32)17 (8)
11025453 (44)285 (63)70 (15)139 (31)41 (9)
2961464 (48)298 (64)101 (22)151 (33)56 (12)
3924466 (50)308 (66)134 (29)156 (33)60 (13)
5855444 (52)294 (66)170 (38)161 (36)64 (14)
7732374 (51)255 (68)182 (49)142 (38)58 (16)
10664361 (54)255 (71)192 (53)142 (39)62 (17)
  • * Treated since symptom onset to baseline.